Autus Valve

Executive Summary

Autus Valve Technologies is a clinical-stage medical device company developing the first synthetic, size-adjustable surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease. Founded in 2019 and headquartered in San Francisco, the company addresses a critical unmet need: existing prosthetic valves do not grow with children, necessitating multiple high-risk open-heart surgeries as the child matures. Autus’s novel valve is engineered to be implanted in a minimally invasive procedure and then percutaneously expanded over time to match the patient's growth, potentially reducing the lifetime number of surgeries from three or more to one. The device is constructed from durable synthetic materials that resist calcification and thrombosis, offering advantages over bioprosthetic and mechanical valves. Autus is currently in the preclinical/early clinical stage, having completed benchtop and animal studies. The company aims to initiate a first-in-human feasibility study within the next 12–18 months. Given the large addressable market (over 1 million children worldwide with congenital heart defects requiring valve replacement) and the strong clinical rationale, Autus Valve represents a compelling investment opportunity. Key risks include the technical challenges of long-term adjustability and the need for substantial capital to fund clinical trials. However, if successful, the product could become the standard of care for pediatric pulmonary valve replacement.

Upcoming Catalysts (preview)

• Q3 2026FDA IDE Approval for First-in-Human Study70% success
• Q2 2026Grant of FDA Breakthrough Device Designation60% success
• H2 2026Series A or B Financing Round50% success